Amantadine and anticholinergics

Handbook of Parkinson's Disease, Fourth Edition

Volumn , Issue , 2007, Pages 293-307

  Dashtipour, Khashayar ^a   Chung, Joseph S ^b   Wu, Allan D ^c   Lew, Mark F ^d  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78449244955     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (91)

1. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208(7):1168-1170.
2. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm 1995; 46:399-405.
3. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987; 10(6):522-526.
4. Adler CH, Stern MB, Vernon G, Hurtig HI. Amantadine in advanced Parkinson's disease: good use of an old drug. J Neurol 1997; 244(5):336-337.
5. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56(11): 1383-1386.
6. Farnebo LO, Fuxe K, Goldstein M, Hamberger B, Ungerstedt U. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur J Pharmacol 1971; 16(1):27-38.
7. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991; 48(9):977-981.
8. Ruzicka E, Streitova H, Jech R, et al. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. J Neural Transm 2000; 107(11):1297-1306.
9. Deeter RG, Khanderia U. Recent advances in antiviral therapy. Clin Pharm 1986; 5: 961-976.
10. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Phar-macokinet 1988; 14(1):35-51.
11. Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, Morselli PL. Effect of amantadine on drug-induced parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmacol 1976; 3(5):883-889.
12. Fahn S, Craddock G, Kumin G. Acute toxic psychosis from suicidal overdosage of aman-tadine. Arch Neurol 1971; 25(1):45-48.
13. Symmetrel® (amantadine) package insert. Chadds Ford, PA: Endo Pharmaceuticals, 2003.
14. Trappler B, Miyashiro AM. Bupropion-amantadine associated neurotoxicity. J Clin Psychiatry 2000; 61:61-62.
15. Wilson TW, Rajput AH. Amantadine-dyazide interaction. Can Med Assoc J 1983; 129(9):974-975.
16. Factor SA, Molho ES. Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord 1999; 14(3):515-517.
17. Greulich W, Fenger E. Amantadine in Parkinson's disease: pro and contra. J Neural Transm 1995; 46:415-421.
18. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 1975; 25:603-606.
19. Dallos V, Heathfield K, Stone P, Allen FA. Use of amantadine in Parkinson's disease. Results of a double-blind trial. Br Med J 1970; 4(726):24-26.
20. Mann DC, Pearce LA, Waterbury LD. Amantadine for Parkinson's disease. Neurology 1971; 21(9):958-962.
21. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane database Syst Rev 2003; (1):CD003468.
22. Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20(5):523-539.
23. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58(1):11-17.
24. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46(6):1551-1556.
25. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50(5):1323-1326.
26. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003; (2):CD003467.
27. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75(1):141-143.
28. da Silva-Junior FP, Braga-Neto P, Sueli Monte F, et al. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005; 11(7):449-452.
29. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000; 47(4 suppl 1):S122-S129; discussion S129-S130.
30. Timberlake WH, Vance MA. Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 1978; 3(2):119-128.
31. Vollum DI, Parkes JD, Doyle D. Livedo reticularis during amantadine treatment. Br Med J 1971; 2(762):627-628.
32. Sladden MJ, Nicolaou N, Johnston GA, et al. Livedo reticularis induced by amantadine. Br J Dermatol, 2003; 149(3):656-658.
33. Quinn NP. Anti-parkinsonian drugs today. Drugs 1984; 28(3):236-262.
34. Shulman LM, Minagar A, Sharma K, Weiner WJ. Amantadine-induced peripheral neuropathy. Neurology 1999; 53(8):1862-1865.
35. Evidente VG, Adler CH, Caviness JN, et al. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharm 1999; 22(1):30-32.
36. Singer C, Papapetropoulos S, Gonzalez MA, et al. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov Disord 2005; 20(7):873-877.
37. Shulman LM, Minagar A, Sharma K, et al. Amantadine-induced peripheral neuropathy. Neurology 1999; 53(8):1862-1865.
38. Schwab RS, Poskanzer DC, England AC, Jr., Young RR. Amantadine in Parkinson's disease. Review of more than two years' experience. JAMA 1972; 222(7):792-795.
39. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 1998; 13(1):34-38.
40. Hughes B, Feiz V, Flynn SB, et al. Reversible amantadine-induced corneal edema in an adolescent. Cornea 2004; 23(8):823-824.
41. Fraunfelder FT, Fraunfelder FW. Drug-Induced Side Effects and Drug Interactions, 5th ed. Boston: Butterworth and Heinemann, 2001:421-422.
42. Blanchard DL. Amantadine caused corneal edema. Cornea 1990; 9:181.
43. Ohta K, Matsushima E, Matsuura M, et al. Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient. World J Biol Psychiatry 2000; 1:59-64.
44. Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 1998; 50(5):1456-1458.
45. Simpson DM, Davis GC. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 1984; 141(6):796-797.
46. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39(7):708-716.
47. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 1982; 17(1):19-23.
48. Blye E, Lorch J, Cortell S. Extracorporeal therapy in the treatment of intoxication. Am J Kidney Dis 1984; 3(5):321-338.
49. Stromberg U, Svensson TH. Further studies on the mode of action of amantadine. Acta Pharmacol Toxicol 1971; 30(3):161-171.
50. Scatton B, Cheramy A, Besson MJ, Glowinski J. Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 1970; 13(1):131-133.
51. Von Voigtlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. Science 1971; 174(7):408-410.
52. Allen RM. Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol 1983; 6(suppl 1):S64-S73.
53. Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm 1995; 46:97-105.
54. Grelak RP, Clark R, Stump JM, et al. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science 1970; 169(941):203-204.
55. Maj J, Sowinska H, Baran L. The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia 1972; 24(2):296-307.
56. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharma- copsychiatry 1999; 32(2):47-55.
57. Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 1992; 213(3):439-443.
58. Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 1992; 263(2):717-724.
59. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 1997; 21(4):455-468.
60. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991; 206(4):297-300.
61. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992; 42:733-738.
62. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neurobiol 1996; 12(1):73-94.
63. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349(6308): 414-418.
64. Rajput A, Wallukait M, Rajput AH. 18 month prospective study of amantadine (Amd) for dopa (LD) induced dyskinesias (DK) in idiopathic Parkinson's disease. Can J Neurol Sci 1997; 24:S23.
65. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23:82-85.
66. Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000; 15(5):873-878.
67. Shoulson I, Penney J, McDermott M, et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001; 56(4):455-462.
68. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 1996; 736(1-2):202-205.
69. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995; 701(1-2):13-18.
70. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998; 13(5):798-802.
71. Ferreira JJ, Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol 2000; 13(4):431-436.
72. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(11 suppl 5):S1-S88.
73. Friedman Z, Neumann E. Benzhexol-induced blindness in Parkinson's disease. Br Med J 1972; 1(800):605.
74. Duvoisin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostig-mine. JAMA 1968; 206(9):1963-1965.
75. de Leon J, Canuso C, White AO, Simpson GM. A pilot effort to determine benztropine equivalents of anticholinergic medications. Hosp Comm Psychiatry 1994; 45(6):606-607.
76. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003; (2):CD003735.
77. Schrag A, Schelosky L, Scholz U, Poewe W. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord 1999; 14(2):252-255.
78. Weiner WJ, Lang AE. Parkinson's Disease. In: Movement Disorders, A Complete Survey. New York: Futura Publishing Co., 1989:95.
79. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23(1):73-78.
80. Hyson HC, Jog MS, Johnson A. Sublingual atropine for sialorrhea secondary to parkinsonism. Parkinsonism Related Disord 2001; 7(suppl):194.
81. Marjama-Lyons J, Koller W. Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 2000; 16(4):273-278.
82. Nastuk WL, Su P, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264(5581):76-79.
83. Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 1984; 82(3):147-150.
84. Bedard MA, Lemay S, Gagnon JF, Masson H, Paquet F. Induction of a transient dysexec-utive syndrome in Parkinson's disease using a subclinical dose of scopolamine. Behav Neurol 1998; 11(4):187-195.
85. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003; 54(2):235-8.
86. Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985; 18(1):35-40.
87. Whitehouse PJ, Hedreen JC, White CL, 3rd, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13(3):243-248.
88. Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltrans-ferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982; 232(1):129-139.
89. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Canad Med Ass J 1962; 87:802-807.
90. Coyle JT, Snyder SH. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 1969; 166(907):899-901.
91. Olney JW, Price MT, Labruyere J, et al. Anti-parkinsonian agents are phencyclidine agonists and N-methyl- aspartate antagonists. Eur J Pharmacol 1987; 142(2):319-320.